Hexarelin: a potent GH peptide — with cortisol, prolactin and desensitization in the fine print

Hexarelin sits at the potent end of the growth-hormone-secretagogue family — a synthetic hexapeptide that, dose for dose, is one of the strongest GH-releasing peptides ever put into people. That potency is the entire pitch, and it’s genuinely backed by a real pharmacology literature. But the honest story has three parts the marketing leaves out: hexarelin isn’t selective the way ipamorelin is, its effect on GH fades with repeated dosing, and it lives entirely in the unapproved, gray-market, WADA-banned category. Potent is not the same as clean, durable, or safe.

What it is

Hexarelin (examorelin) is a synthetic hexapeptide growth-hormone-releasing peptide— a GHRP in the same broad family as the ghrelin mimetics, designed to trigger the pituitary to release a pulse of its own growth hormone rather than injecting GH directly. It works at the GH secretagogue receptor (the ghrelin receptor), the same axis targeted by ipamorelin and CJC-1295 and by the oral ghrelin mimetic MK-677. Where hexarelin stands apart is sheer potency: in controlled human work it is among the most powerful GH-releasing peptides studied, producing a brisk, large GH pulse after a single subcutaneous dose.^[1]

What is actually proven: a strong GH pulse

The strongest evidence for hexarelin is mechanistic and human. In direct comparison studies it released substantially more GH than GHRH and held its own against ghrelin itself, confirming that the “it raises growth hormone” claim is genuinely supported.^[1] That is the high-water mark of the evidence — a real, measured pharmacodynamic effect on a surrogate marker. As with every peptide in this family, raising GH is the means; there are no rigorous, well-powered human trials showing that hexarelin’s GH spike translates into the muscle, fat-loss, recovery or anti-aging outcomes it is sold for. (For the broader pattern, our ipamorelin & CJC-1295 evidence reviewwalks through why “raises GH” and “changes the body” are two different claims.)

The first downside the marketing skips: it isn’t selective

Ipamorelin earned its reputation for a specific reason — it was characterized as the first selective GH secretagogue, raising GH with little effect on cortisol or prolactin.^[3] Hexarelin is not that. In a controlled human study of repeated daily subcutaneous injections, hexarelin raised not only 24-hour GH but also prolactin, ACTH and cortisol— the adrenal and lactotroph axes ride along with the GH effect.^[2] A separate human comparison confirmed hexarelin’s endocrine activity is broader than that of the natural ligand, spilling into ACTH/cortisol and prolactin release.^[1] That spillover matters: chronically nudging cortisol upward is the opposite of what most people stacking a “recovery” peptide think they’re buying.

The second downside: the GH response fades (tachyphylaxis)

A single hexarelin injection produces a dramatic GH spike — but that is not the same as a sustained elevation. The GH response to hexarelin shows tachyphylaxis: with continued administration the pituitary desensitizes and the GH output attenuates over time. A study of long-term hexarelin therapy documented that the GH response is not maintained at the initial magnitude through chronic dosing.^[4] Practically, that undercuts the whole premise of running hexarelin as a standing protocol: the very effect being purchased is the one that erodes the longer it’s used. It is a property of the molecule, not a dosing error you can outrun with more.

The part that is genuinely interesting: cardiovascular biology via CD36

Hexarelin does have a serious research story that’s independent of growth hormone — and it deserves credit because it’s often the most-distorted part of the marketing. Hexarelin binds the CD36 scavenger receptor, and a body of preclinical work shows it exerts direct cardiovascular actions through CD36 in heart and vascular tissue, separate from the GH axis.^[5]In macrophages, a hexarelin-class GHRP acting at CD36 up-regulated sterol transporters and promoted cholesterol efflux through a PPAR-γ-dependent pathway — an anti-atherogenic mechanism of real scientific interest.^[6] The honest framing: this is mechanistic and largely preclinicalbiology, not evidence that hexarelin is a heart drug you should take. It explains why hexarelin is studied; it does not make it a therapy.

The supply and safety problem

Hexarelin is not an approved drug for any of the uses it’s marketed for. It is sold almost entirely as “research-use-only” material that is not manufactured to pharmaceutical standards, which means dose, purity and even identity in the vial are unverified — the same gray-market hazard we lay out in where to get peptides safely and price out in peptide therapy cost. As a growth hormone secretagogue it is also prohibited in sport by WADA. Layer the cortisol and prolactin spillover and the fading GH response on top of an unregulated supply chain, and the risk-to-reward case is weak: you are buying an unverified product whose most-marketed benefit desensitizes and whose side channels run in the wrong direction.

The honest bottom line

Hexarelin is real pharmacology, not snake oil — it is one of the most potent GH secretagogues ever studied, with a legitimate human GH literature and a genuinely interesting CD36 cardiovascular biology. But potency is the only thing it wins on. It is non-selective (it raises cortisol and prolactin, where ipamorelin does not), its GH effect fades with repeated use, it has no human outcome data for the muscle/anti-aging uses it’s sold for, and it lives in the unapproved, WADA-banned gray market. If you’re drawn to a secretagogue, the selective ipamorelin better matches the “clean GH signal” intent; for how these compounds line up against the injectable GHRH analogs, see ipamorelin vs sermorelin and our MK-677 evidence review. To grade hexarelin against the rest of the field, use the peptide evidence matrix; to compare the legitimate, regulated provider options, see our peptide therapy comparison.